Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255405 | SCV000321995 | pathogenic | not provided | 2023-08-27 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 16963483, 28559085) |
Blueprint Genetics | RCV001074717 | SCV001240310 | likely pathogenic | Retinal dystrophy | 2019-04-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000255405 | SCV001379478 | pathogenic | not provided | 2024-01-18 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys768*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 16963483, 28559085). ClinVar contains an entry for this variant (Variation ID: 265286). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003454778 | SCV004182439 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003454778 | SCV004206457 | pathogenic | Retinitis pigmentosa 39 | 2021-10-29 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271235 | SCV001452247 | pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |